Table 2.
Results of the Matched Case-control Study
| Variable | Case Patients (N = 10) | Control Patients (N = 40) | Matched Odds Ratio | 95% Confidence Interval | P Value |
|---|---|---|---|---|---|
| Demographics | |||||
| Median age, y (range) | 64 (51 to 85) | 64 (24 to 87) | … | … | 1.00b |
| Non-white race | 0 (0.0%) | 7 (17.5%) | 0.36a | (0 to 2.08) | .37 |
| Male gender | 6 (60%) | 20 (50.0%) | 1.55 | (.35 to 6.82) | .57 |
| Comorbidities | |||||
| Median Charlson comorbidity index (range) | 6.5 (1 to 10) | 5 (0 to 15) | … | … | .22b |
| Solid organ transplant | 3 (30%) | 9 (23.1%) | 1.97 | (.25 to 15.73) | .52 |
| Immunosuppression | 3 (30%) | 10 (25.6%) | 1.46 | (.22 to 9.54) | .70 |
| Diabetes mellitus | 4 (40%) | 15 (37.5%) | 1.12 | (.26 to 4.84) | .88 |
| History solid organ malignancy | 5 (50%) | 7 (17.5%) | 4.45 | (1.01 to 19.71) | .05 |
| History hematologic malignancy | 0 (0%) | 2 (5.0%) | 1.66a | (0 to 13.89) | .99 |
| End-stage liver disease | 3 (30%) | 9 (22.5%) | 2.31 | (.25 to 21.11) | .46 |
| Chronic renal insufficiency | 2 (20%) | 10 (25.0%) | 0.73 | (.12 to 4.39) | .73 |
| VRE status | |||||
| VRE infection | 10 (100%) | 1 (2.5%) | 52.18a | (10.67 to infinity) | <.001 |
| Prior VRE colonization | 3 (30%) | 10 (25.0%) | 1.33 | (.26 to 6.80) | .73 |
| Prior clinical VRE infection (5 y) | 0 (0%) | 1 (2.5%) | 4 | (0 to 76.00) | >.99 |
| IR procedure | |||||
| IR | 9 (90%) | 12 (30.0%) | 16.72 | (2.01 to 138.73) | .009 |
| IR with contrast | 9 (90%) | 3 (7.5%) | 39.35a | (7.85 to infinity) | <.001 |
| Median days from IR to positive VRE culture (range) | 12 (2 to 22) | 8 (6 to 6) | … | … | .32b |
Abbreviations: IR, interventional radiology; VRE, vancomycin-resistant enterococci.
aMedian unbiased estimate calculated.
bWilcoxon test performed.